212 Pb-trastuzumab

N/A

Report date: 2025/11/04 16:07:40

Base Information

Drug Name212 Pb-trastuzumab

Drug Alias Name212 Pb TCMC trastuzumab212 Pbtrastuzumab212Pb-TCMC-trastuzumab

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Radioactive therapeutic agent +[5]

Mechanisms of ActionIonising radiation emittersReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsNeoplasm Metastasis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAreva Pharmaceuticals

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAreva Pharmaceuticals University Of Cincinnati University Of Alabama At Birmingham

Active IndicationsN/A

Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A